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Abstract
Biomarkers derived from gene expression profiling data may have a high false-positive rate and must be rigorously
validated using independent clinical data sets, which are not always available. Although animal model systems could
provide alternative data sets to formulate hypotheses and limit the number of signatures to be tested in clinical samples,
the predictive power of such an approach is not yet proven. The present study aims to analyze the molecular signatures of
liver cancer in a c-MET-transgenic mouse model and investigate its prognostic relevance to human hepatocellular
carcinoma (HCC). Tissue samples were obtained from tumor (TU), adjacent non-tumor (AN) and distant normal (DN) liver in
Tet-operator regulated (TRE) human c-MET transgenic mice (n = 21) as well as from a Chinese cohort of 272 HBV- and 9 HCV-
associated HCC patients. Whole genome microarray expression profiling was conducted in Affymetrix gene expression
chips, and prognostic significances of gene expression signatures were evaluated across the two species. Our data revealed
parallels between mouse and human liver tumors, including down-regulation of metabolic pathways and up-regulation of
cell cycle processes. The mouse tumors were most similar to a subset of patient samples characterized by activation of the
Wnt pathway, but distinctive in the p53 pathway signals. Of potential clinical utility, we identified a set of genes that were
down regulated in both mouse tumors and human HCC having significant predictive power on overall and disease-free
survival, which were highly enriched for metabolic functions. In conclusions, this study provides evidence that a disease
model can serve as a possible platform for generating hypotheses to be tested in human tissues and highlights an efficient
method for generating biomarker signatures before extensive clinical trials have been initiated.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
malignancy worldwide, with over 300,000 new cases per year in
China and with a rising incidence in western countries [1].
Surgical resection or liver transplantation are the primary
treatment options for HCC patients having a 5-year survival rate
at 50–60% [2]. Unfortunately, about 80% of patients are
diagnosed in advanced stages at presentation and are essentially
inoperable and refractory to most of the conventional chemother-
apies [3]. As such, there is an urgent need to identify prognostic
markers of HCC [4,5,6,7,8,9] and to develop targeted therapies
through conventional small molecule inhibitors and/or RNAi
therapeutics [10,11,12,13,14].
Several intricate transgenic mouse models of human cancer
have been suggested to accurately mimic the pathophysiology and
molecular features of human malignancies [15], but cross-species
gene-expression comparisons of the animal models and human
disease are not available for validation [16]. HCC develops in
humans as a progressive disease from a cirrhosis predisposition
caused by hepatitis B or C virus infection, chronic alcoholism, or
aflatoxin exposure. As a result, human HCC tumor tissue is
surrounded by premalignant cirrhotic tissue [17]. A transgenic
mouse model of HCC has been developed by Bishop and
colleagues in which tumors are induced by liver-specific,
tetracycline-regulated (TRE) expression of a human c-MET
kinase transgene, a genetic lesion commonly associated with
human liver tumors [18]. The tumors that arise due to c-MET
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over-expression in the mouse resemble human HCC at the level of
histology [19]. Activating mutations in b-catenin leading to
upregulation of the Wnt signaling pathway, another common
feature of human HCC, were frequently observed in these tumors.
Nevertheless, information on tumor suppressor gene TP53, which
is commonly mutated in human HCC [20], and other potential
gene targets in this model system are not available. Furthermore,
the molecular character of the adjacent non-malignant tissue
surrounding the tumors is not well studied and characterized [21].
A better understanding of how the mouse model compares with
human disease at the molecular level is therefore crucial to the
design and interpretation of efficacy studies for therapies.
Biomarkers derived from microarray expression profiling
data can be subject to high false-positive rate due to multiple
hypothesis testing inherent to working with large numbers of
genes and gene combinations. A predictive biomarker signature
or gene set determined from a given set of samples (the training
set) must be validated with data from independent samples (the
test/validation set) [22,23]. Meeting this goal can be challeng-
ing as independent data sets, especially those from clinical
samples treated in a similar manner, are scanty or require
significant time investment to accumulate. One work-around to
this limitation is to formulate and test hypotheses using data
from a model system.
In this study, we performed molecular profiling of normal liver
and tumor tissues from the c-MET driven mouse model, to
understand the molecular changes in these mice. We determined
how well the model approximates human disease and confirmed
the expression of specific cancer targets. We used the data derived
from the c-MET model to generate signatures distinguishing
tumor (TU) from adjacent non-tumor (AN) and wild-type (WT)
normal tissues, and tested the prognostic power of these signatures
in a data set from human HCC.
Methods
Ethics
The Institutional Review Board of the University of Hong
Kong/Hospital Authority Hong Kong West Cluster (HKU/HA
HKW IRB) approved this study, and each patient gave his/her
written informed consent on the use of the clinical specimens for
research. All studies involving animals were fully approved by the
Merck Boston Institutional Animal Care and Use Committee
(protocol numbers: #07-08-044 and #08-08-041) and were
conducted according to the institutional animal ethics guidelines.
The c-MET mouse HCC model
The mice used in this study have been described (Table 1) [18,24].
All mice were on an FVB genetic background. Mice overexpressing
human c-MET carried one copy of the LAP-tTa transgene (the liver-
specific LAP promoter driving the Tet-VP16 transactivator) and one
copy of the TRE-c-MET transgene (Tet-operator regulated human c-
MET gene). The presence of both transgenes results in expression of
the human c-MET gene specifically in and throughout the liver
(referred to henceforth as the TRE-c-MET strain). Seven mice of each
strain were sacrificed at six (TRE-c-MET), seven (LAP-tTa) or 14
(TRE-c-MET) weeks of age. Normal liver or liver tumor tissue (two per
mouse) was collected and processed for gene expression profiling at the
Rosetta Gene Expression Laboratory. In addition, adjacent liver tissue
was collected from the non-involved tissue next to the border of the
tumor in the tumor-bearing liver lobe. Distant liver tissue was from a
non-tumor bearing lobe or from areas at least 1 cm away from the
tumor. Animal works were conducted in AALAC-accredited labora-
tory according to the institutional animal ethics guidelines.
Patient cohorts and clinical samples
All patients that were enrolled in this study underwent a
curative hepatectomy for HCC at Queen Mary Hospital,
Pokfulam, Hong Kong between 1993 and 2007 [3,25]. This study
was approved by the Institutional Review Board for Human Ethics
and each patient gave his/her written informed consent on the use
of the clinical specimens for research. Liver tissue that was
obtained from patients at the time of the curative surgery was
immediately snap-frozen in liquid nitrogen and stored at 280uC
until required.
Microarray and analysis
Total RNA was extracted and purified from the clinical liver
specimens (n = 272 HBV-HCC tumor (TU), 257 HBV-HCC
tumor-adjacent normal (AN), 9 HCV-HCC tumor (TU).
9 HCV-HCC tumor-adjacent normal (AN)) using the SV96
Total RNA Isolation System (Promega) according to a custom
automated protocol. The extracted RNA was quantified using
RiboGreen RNA Quantitation Reagent (Invitrogen) and its
quality was assessed using Agilent RNA 6000 Pico Kit (Agilent,
Santa Clara, CA) in an Agilent 2100 Bioanalyzer (Agilent). Only
those samples passing the minimum thresholds for quantity and
quality (RIN.6) were amplified and labeled using the Ovation
WB protocol (NuGEN Technologies, San Carlos, CA), according
to the manufacturer’s instructions. In brief, 50 ng of total RNA
was amplified using the Ribo-SPIA technology (NuGEN Techno-
logies),fragmented and labeled with biotin using the FL-Ovation
cDNA Biotin Module V2 (NuGEN Technologies). The resulting
amplified cRNAs were hybridized to Affymetrix gene expression
chips (Human Rosetta Custom Affymetrix 1.0, Affymetrix, Santa
Clara, CA) [26]. The images were analyzed using the standard
package of Affymetrix GeneChip Operating Software (GCOS)
(www.affymetrix.com/products/software/specific/gcos.affx) and
were further normalized and processed to derive the sequence-
based intensities using the RMA algorithm as implemented in
Affymetrix Power Tools (http://www.affymetrix.com/support/
developer/powertools). Data used for this analysis passed two
levels of quality controls (QCs) (array level using Affymetrix
recommended parameters, and project level on excluding outlier
arrays and arrays with major patterns associated with known
process parameters). Log10(ratio) of each gene in each sample
were computed by subtracting mean of log10(Intensity) of that
gene across all adjacent non-tumor samples, to make them
comparable to the c-MET mouse model data where the references
are the pool of wild-type mouse liver tissues. Raw gene expression
profiling data were deposited to GEO with the following accession
Table 1. Mouse signatures identify gene sets with predictive
power for survival in human samples.
Tumor
Down
(p-value)
Up
(p-value)
WT 9.561026 0.07
AN 2.061025 0.10
DN 2.361025 0.06
Pair-wise comparison between tumors and wild type (WT), adjacent non-tumor
(AN) or distant normal (DN) liver samples identified expression signatures for
genes that were either down-regulated or up-regulated in the tumors. The p-
values for the ability of these signatures to predict survival in human patients is
indicated based on K-M curves in Figure 3.
doi:10.1371/journal.pone.0024582.t001
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numbers: GSE25142 (derived from the c-Met mouse model) and
GSE25097 (derived from human HCC).
Tumor signature from mouse profiles
We used one-way ANOVA to define tumor signature in mice c-
MET experiment, say, for a comparison between WT Vs. tumor,
we identified 6277 mouse probesets with ANOVA P-value, 0.001.
The false discovery rate (FDR) here is estimated to be 0.62% from
1000 permutations. Among those signature probesets, 3114 showed
tumor down- and 3163 tumor up-regulations compared with WT.
The mouse tumor signature was then mapped to human probesets
in Affymetrix human chip. We also identified mouse tumor
signature from comparisons of adjacent non-tumor vs. tumor and
distant non-tumor vs. tumor, by ANOVA analysis.
Biological annotation and geneset enrichment test
We compiled many databases include gene sets with known
biological functions or properties from a variety of public (GO
cellular components, molecular function, biological processes,
KEGG pathways, SwissProt Keywoards, etc.), licensed (GeneGo,
Ingenuity, NextBio biosets, etc.), and proprietary sources (internal
compound, siRNA, body atlas profiling, etc.). These annotated
gene sets were used in the enrichment test. The enrichment P-
values (the chance probability of observing overlapping genes
between the input geneset and the geneset in the database) is
computed using the hypergeometric distribution [27].
Prognostic power of signatures
To estimate the prognostic power of each of mouse signatures,
the signature was mapped to human probesets and then treated as
a metagene [28,29]. Namely, the expression level for the metagene
in human HCC samples was calculated by averaging log(ratio) of
all the genes mapped from the mouse up- or down-regulated
signatures. The human HCC samples were ranked by the
expression level of the metagene and then divided into two equal
groups by the median value (to avoid the over-fitting, we did not
optimize the threshold). The log-rank P-values between these two
groups were calculated by the log-rank test using time of overall
survival and disease free survival respectively.
Results
Global gene expression changes in mouse and human
HCC
To determine tumor-specific gene expression in the c-MET
mouse model of HCC, we compared tissue from tumor-bearing
mice to several control tissues including adjacent and distant
normal liver tissue from tumor bearing mice, wild-type liver tissue
and liver tissue from two single transgene parental lines (Table S1).
We used wild-type liver tissue (virtual pool from 7 mice) as a
baseline and performed unsupervised clustering of differentially-
expressed genes. We found that the tumors had a distinct
expression pattern (Figure 1A). To characterize the molecular
nature of the differentially expressed genes, we performed Gene
Ontology biological annotation [30] (see also Supplementary
Information) on each gene set and found that the down-regulated
genes were enriched for metabolic processes, whereas the up-
regulated genes were enriched for cell cycle and cytoskeleton-
related terms (Table S2). Gene expression changes in human HCC
showed similar GO annotations (Table S3), indicating that on a
global gene expression level, the c-MET mouse model approxi-
mates human HCC.
We performed unsupervised clustering and found that the
expression profiles of adjacent and distant normal tissue samples
were interspersed, segregated by the animal from which they were
taken and distinct from the tumor profiles (Figure 1A). This result
indicates that tumor proximity does not significantly alter gene
expression in the normal liver tissue. However, subtle differences
between the adjacent and distant samples may exist.
Although both HCV- and HBV-infection have been shown to
cause HCC, HBV infections were predominant in this cohort (272
HBV-HCC tumors and 9 HCV-HCC tumors). To identify
potential molecular differences between HCV- and HBV-infected
HCC, we analyzed all available HCV samples in this cohort (nine)
and compared them to an equal number of randomly selected
HBV samples (nine). The HBV samples were randomly
distributed in an unsupervised cluster of all tumor samples (data
not shown) indicating that they were not skewed toward a
particular molecular profile. We did not observe any consistent
molecular difference among these samples (data not shown).
To determine whether parallels between human and mouse
HCC exist at the gene level, we performed direct comparison of
the mouse and human HCC profiles. The mouse samples were
normalized against wild-type liver tissue (virtual pool from 7 mice)
and the human samples were normalized against an average of all
adjacent non-tumor samples. Unsupervised clustering of the
human and mouse samples showed that the molecular profiles of
the two tumor sets were more closely related to each other than to
their cognate adjacent non-tumor tissues (Figure 1B, red box),
revealing a tumor-specific molecular signature.
Among the genes differentially expressed in the majority of
mouse and human tumors, we identified three gene subsets with
distinct characteristics (Figure 1B, yellow boxes). Two groups
showed similar expression patterns in both tumor types: genes
down-regulated in both tumor types were enriched for metabolic
processes, whereas genes up-regulated in both tumor types were
enriched for cell cycle processes. Genes down-regulated specifically
in the human tumors were enriched for immune response
processes, reflecting a molecular distinction that may point to
differences in tumor progression mechanisms. In summary,
comparison of the molecular profiles of human and mouse HCC
revealed extensive parallels at the gene expression level. However,
each set of tumors was also characterized by specific gene
expression patterns.
Down-regulation of genes involved in metabolic processes in the
tumors suggests that liver functions are diminished or impaired.
To explore liver identity in these tumors further, we examined the
expression of liver-enriched genes [31,32,33] and found that they
were down-regulated in the tumor samples (Figure 1C), consistent
with loss of liver identity and function with tumor progression.
Activity of oncology pathways in HCC
To gain a better understanding of the activity of signaling
pathways relevant to oncology in the c-MET model of HCC, we
performed targeted analysis of the expression changes using
pathway signatures defined previously. The Wnt/b-catenin
signature consists of genes up- and down-regulated by b-catenin
siRNAs in DLD-1 colon carcinoma cells [34]. We found elevated
Wnt pathway activity (Figure 2A), consistent with the activating
mutations of b-catenin frequently detected in these tumors and
activation of the Wnt pathway in one third of HCCs [35].
Unsupervised clustering of the mouse and human samples showed
a relationship between a subset of human HCC profiles and the
mouse tumor samples (Figure 2B), indicating that the c-MET
mouse may be a useful model for studying HCC patients with
activated Wnt signaling. Interestingly, the genome-wide profiles of
the mouse tumors and the subset of human HCC with up-
regulated Wnt pathway expression were not correlated (correla-
Prognostic Gene Signatures of Liver Malignancy
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Figure 1. Molecular profiling of the mouse c-MET HCC tumor model. (A) Global gene expression analysis revealed tumor-specific gene
expression changes characterized by genes down-regulated in tumors that were enriched for metabolic processes (white box) and genes up-
regulated in tumors that were enriched for cell cycle and actin cytoskeleton (yellow). Non-tumor tissues adjacent to or distant from the tumors
showed similar expression patterns are were interspersed in the heat map generated by unsupervised clustering, with samples from the same animal
clustering together. The vertical bars to the right of each heat map represent color coding of the samples that corresponds to the legend in each
panel. (FVB-WT, purple) Liver tissue from control animals; (LAP-tTA, dark blue and TRE-c-MET, orange) liver tissue from single transgene parental
strains; (c-MET TU, green) tumor tissue from double transgene, tumor bearing animals; (c-MET AN, light blue) non-tumor liver tissue from double
transgene, tumor-bearing animals adjacent to tumor; (c-MET DN, red) non-tumor liver tissue from double transgene, tumor-bearing animals distant
from tumor. The heat map represents unsupervised clustering of differentially-expressed genes (fold change $1.25, p,0.01, Cluster Algorithm:
Agglomerative, Similarity Measure: Cosine correlation). (B) The majority of liver-enriched genes were down-regulated in the c-MET tumors, consistent
with loss of liver function. For this analysis, we selected the top 400 genes with the greatest fold-change from the liver-enriched genes identified by
Su and colleagues [18]. A small subset of genes that were up-regulated (yellow boxes) may contain useful biomarkers of tumor presence. Color
legend 20.5,log10 (ratio),0.5. (C) Comparison of mouse c-MET and human HCC tumor profiles. Human and mouse tumor samples co-clustered
indicating similar gene expression patterns (red box). The differentially expressed genes can be divided into three groups on the basis of their specific
Prognostic Gene Signatures of Liver Malignancy
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tion= 0.07). This is in contrast to the significant correlation
observed for the focused Wnt signaling pathway gene set,
indicating that the similarities are restricted to specific pathways.
p53 pathway activity in the mouse HCC model is of interest as
TP53 mutations are common (in ,27% of cases) in human HCC
[20]. We used a p53 pathway signature [36] and observed up-
regulation of the p53 pathway in the mouse HCC tumors,
demonstrating a difference from human HCC (Figure 2C). In
contrast, human HCC samples did not show p53 pathway up-
regulation (Figure 2D), presumably due to mutations or other
p53-inactivating mechanisms. These results indicate that al-
though the mouse c-MET model may replicate a subset of human
HCCs in several aspects, molecular differences do exist and
should be taken into account when data obtained from this model
are analyzed, particularly for targets in the p53 pathway. This is
largely due to the wild-type status of p53 gene in the mouse
model. Thus, special attention and consideration should be paid
when comparing the cross-species human disease model. The
Wnt signaling pathway and the p53 pathway are all very
common in cancer development. Gene expression signatures of
both pathways in the mouse tumor model and human HCC were
presented in Figure S2.
Mouse-derived gene signatures have predictive power
for survival of human HCC patients
We identified gene signatures in the mouse tumors by
comparing the tumor gene expression pattern to the three non-
tumor tissues indicated in Table S1 (wild type (WT), adjacent
nontumor (AN) and distant normal (DN) liver). We used the
adjacent vs. tumor signature because it is most analogous to the
regulation patterns (yellow boxes) and GO annotation. (HCC Adj) Human adjacent non-tumor; (HCC TU) human tumor; (c-MET TU) mouse tumor; (c-
MET Adj/Dis) mouse adjacent and distant normal. The heat map represents unsupervised clustering of differentially-expressed genes (fold change
$1.25, p,0.01, Cluster Algorithm: Agglomerative, Similarity Measure: Cosine correlation).
doi:10.1371/journal.pone.0024582.g001
Figure 2. Activity of oncogenic pathways in mouse c-MET tumors and HCC. (A) The Wnt/b-catenin pathway was up-regulated in the mouse
tumors as measured by the Wnt/b-catenin gene signature [34]. The genes in each signature are indicated across the top of each heat map. The
samples are on the Y-axis and their tissue of origin is indicated in the vertical color-coded bar to the right of each heat map. Color-coding legend for
panels A and C is between the panels. All abbreviations are as in Figure 1. (B) The Wnt/b-catenin pathway was up-regulated in a subset of human HCC
patients as illustrated by the three human samples (HCC TU, purple) that co-cluster with the mouse HCC samples (c-MET TU, yellow). Color-coding
legend for panels B and D is between the panels. (C) The tp53 pathway was up-regulated in the mouse tumors(c-MET TU, green). (D) Up-regulation of
the tp53 pathway was specific to the mouse model (c-MET TU, yellow) and was not observed in human HCC (HCC TU, purple).
doi:10.1371/journal.pone.0024582.g002
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comparison of the clinical samples in our study. The distant vs.
tumor signature provides further information about any effects
that tumor proximity may exert on the adjacent tissue. Finally,
given that both the adjacent and the distant tissues also express
the c-MET transgene, we included the wild-type vs. tumor
signature to identify any c-MET-driven gene expression changes.
For each pair-wise tissue comparison, we identified sets of genes
that were down- or up-regulated in the tumor and generated heat
maps using these genes and the mouse c-MET tumor and FVB-
WT wild-type samples shown in Figure 3A and Figure S1. We
then projected those signatures to the human HCC data and
determined their survival predictive power and their expression
pattern. The entire cohort of patients was used in this analysis and
the human samples were divided into two groups based on the
average log(ratio) of all genes in the signature as described in the
Materials and Methods.
Interestingly, we found that for all comparisons, the genes
down-regulated in the tumors had highly predictive power for
patient survival (Table 1) and disease free survival (Table S4). As
shown previously, these genes were enriched for metabolic
processes both in humans and mouse. In contrast, the up-
regulated signature, enriched for cell cycle processes, did not have
very high predictive power for survival (Table 1) or disease free
survival (Table S4). Figure 3B and Figure S1 show the Kaplan-
Meier plots for these data. We suggest that the up-regulated cell
cycle processes lack predictive power because they represent
general tumor events, whereas loss of metabolic properties signifies
specific loss of functional properties by the liver cells that may be
detrimental to patient survival.
To determine whether the predictive power of the mouse-
derived signatures is specific to the c-MET model, we analyzed the
predictive power of a signature derived from independent mouse
models [37] and found that a significant portion of the genes had
predictive power (Figure S3). These results indicate that the
predictive power of the mouse-derived genes comes from the
tumor properties of the mouse samples and suggests a general
utility of mouse tumor models for identification of gene signatures
predictive of outcome in human tumors.
Next, we analyzed the expression pattern of the mouse gene
signatures in the human samples and found that the genes
identified in the mouse model showed significant expression
changes in the human tumors (representative heat maps in
Figure 4.) To determine whether the expression changes were in
the same direction in the mouse and human, we calculated the
average expression for each gene in the human tumors compared
with adjacent non-tumor. We found that each of the six mouse
signatures contained genes whose expression changed in the
human tumors both in the same and in the opposite direction. For
example, among the genes down-regulated in mouse tumors vs.
WT tissue (Figure 4A–B), a subset was also down-regulated in
human tumors (Figure 4A) whereas a subset was up-regulated in
human tumors compared to adjacent non-tumor tissues
(Figure 4B). Similarly, among the genes that were up-regulated
in mouse tumors vs. WT tissue, a subset of genes was down-
regulated in the human tumors and a subset was up-regulated
(data not shown).
To understand the difference between the genes regulated in the
same or in the opposite direction in the mouse and human tumors,
Figure 3. Mouse tumor signatures predict human patient survival. (A) Mouse tumor gene expression signatures. Heat maps show the
expression of genes that were differentially expressed between tumor tissue and wild type or adjacent normal tissues in the mouse. (B) The mouse
tumor signatures were split into up-regulated and down-regulated sets and Kaplan-Meier plots were generated for each gene set to test the
predictive power for overall patient survival.
doi:10.1371/journal.pone.0024582.g003
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we analyzed each subset separately for their power to predict
survival (Table 2), disease-free survival (Table S5) and for
enrichment for biological pathways (Table 2). We found that the
genes down-regulated both in mouse and human tumors (Table
S6) retained a highly significant predictive power for survival and
enrichment for metabolic processes. In contrast, the subset of
genes that were down-regulated in the mouse tumors but up-
regulated in human tumors did not have predictive power and
significant enrichment for any biological processes. Among the
genes up-regulated in the mouse tumors, those that were down-
regulated in the human tumors did not have any predictive power
for survival or significant biological annotation (significant
enrichment of biological pathways, as measured by hypergeo-
metric P-value). Interestingly, whereas the entire set of genes up-
regulated in the mouse tumors did not have a predictive power (see
above, Table 1 and Table S4), the subset of genes that were up-
Figure 4. Expression of mouse signature genes in human tumors. Gene signatures generated in mouse tissues were projected onto the
human HKU HCC data set. The color scale is as in Figure 1 (20.5 to 0.5). Mean expression levels are plotted to the right of each heat map to illustrate
the association between expression and prognosis. The K-M curves are given below each heat map.
doi:10.1371/journal.pone.0024582.g004
Table 2. Prognostic power and GO Biological process annotation of mouse signatures split according to their expression in human
samples.
Mouse Down in tumor Up in tumor
Human down up down up
Tumor compared to
WT 6.361026 0.54 0.32 0.021
adjacent 2.761026 0.66 0.51 0.0026
distant 1.161025 0.58 0.45 0.0089
WT metabolism no enrichment cell motility cell cycle
adjacent metabolism no enrichment no enrichment cell cycle
distant metabolism no enrichment cell motility cell cycle
Mouse signatures were split according to the expression of the genes in human tissues. The ability of each gene set to predict overall survival in human samples was
assessed using K-M plots. The p-values for prognosis were calculated and are indicated in the table. Each gene set was analyzed for enrichment of gene ontology
biological pathways.
doi:10.1371/journal.pone.0024582.t002
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regulated in both mouse and human tumors showed marginally
significant predictive power (Table 2, Table S7). This result
indicates that filtering out the discordantly regulated genes
through a model system and clinical samples and retaining only
those that are similarly regulated in both can reveal sets with
predictive power that may not be detected when either the global
signatures of either system are considered separately.
Since the mouse HCCs were induced by c-MET, we repeated
the above analysis in human HCC by focusing on those patients
with high c-MET (patients with HCC c-MET expression .
median expression of the population) to define the signatures in
the same or opposite direction between mouse and human. Similar
to Figure 4 A&B, we identified 775 genes both down regulated in
mouse and human c-MET-high HCC, and 612 genes in the
opposite direction. Among these, 749 overlapped with 800 same
direction genes using all HCC samples (96.7% overlap, hypergeo-
metric P-value 0) and 562 overlapped with 587 opposite direction
genes using all HCC samples (95.7% overlap, hypergeometric P-
value 0). Analogues to Figure 4 and Table 2, we also checked the
prognostic power of these two signatures, the log-rank P-values for
overall survival are 2.261026 and 0.78 respectively, very similar
predictive power as the case where the whole HCC patients were
used to map the overlap signatures (Table 2). Gene ontology of
these overlapping genes was conducted to reveal the biological
pathways associated with different gene sets when comparing the
mouse c-MET driven liver tumors and the human c-MET-high
HCC (Table S8).
Discussion
The present study shows that the mouse c-MET tumor model
has similarities with human HCC at the molecular level including
down-regulation of metabolic processes and up-regulation of cell
cycle genes. Tumor-specific gene signatures derived in the mouse
model can distinguish tumor from non-tumor tissue in human
HCC. The genes down-regulated in tumor compared with
adjacent non-tumor tissue in both the mouse and human samples
had significant predictive power on overall survival and disease-
free survival in HCC patients. These genes were highly enriched
for metabolic function indicating that loss of normal liver function
is related to poor outcome in HCC patients. The predictive power
of the mouse-derived signatures likely stems from their tumor
properties rather than c-MET-driven properties, and underscores
the utility of mouse tumor models for identification of gene
signatures relevant to human disease.
The tumors from the c-MET model had uniform gene
expression profiles as expected for tumors induced by a single
oncogene in an inbred mouse strain. This is in contrast with
human HCC samples, which showed significant differences in
oncology pathway activity and mRNA expression [38,39].
Significantly, by comparing the mouse and human expression
profiles, we found that the mouse model is similar to a subset of
human tumors characterized by high levels of Wnt pathway
activity. Given that Wnt activation is a unique pattern activated in
c-MET induced HCC and that the downregulated metabolic
genes in mouse had prognostic power in human HCC, we
examined the correlation between Wnt activation and metabolic
dysfunction in both mouse and human HCC samples. We found
that metabolic function was anti-correlated with activation of the
Wnt pathway both in animal model and human HCC (Figure 5).
The trend is stronger in mouse than in human, which may indicate
that more factors affect metabolic function in human tumors.
Human cancers are thought to initiate from a single mutated
cell in the context of a normal organ, whereas in the c-MET
mouse model, all liver cells overexpress the oncogene, potentially
creating a different microenvironment for the pre-neoplastic cell.
The mechanism by which only certain cells within the c-MET-
overexpressing liver develop into cancer is unclear at present,
although the presence of a secondary mutation is necessary. We
compared the gene signatures from c-MET overexpressing non-
tumor tissues (adjacent or distant) to signatures from liver tissue of
wild-type mice and did not find any biological annotation or
predictive power (data not shown). The similar predictive power
and biological annotations of the signatures regardless of the
control tissue used in the comparison (wild type, adjacent or
distant) suggests that, on a global level, gene expression changes in
the tumor are minimally influenced by c-MET overexpression
and, for the most part, reflect downstream consequences of tumor
formation. In support of this hypothesis, the c-MET-regulated
genes identified in primary hepatocytes from the c-MET knock-
out mouse [40] did not show significant regulation in the c-MET
overexpressing non-tumor tissues (data not shown). Within our
own human HCC dataset, we found little differences in terms of
mouse and human overlapping down-regulated or up-regulated
tumor to normal signatures no matter whether we used the whole
HCC populations or the subpopulation with higher c-MET
expression. The independence of the tumor signature on c-MET
expression indicates that the tumor signature is not a consequence
of the model-specific tumor-initiating lesion. Rather, the tumor
signature reflects downstream effects of tumor progression that are
analogous in the mouse model and in human disease. These
findings are significant because they underscore the relevance of
the mouse model to human HCC despite the inherent difficulties
in recapitulating human tumor initiation in the mouse.
With respect to human disease, we found that the down-
regulated signature in tumor vs. adjacent non-tumor tissue that is
shared by mouse and human samples has very significant
predictive power on overall survival and disease free survival.
Further refinement of this signature may identify genes that can be
tested as predictive biomarkers in the clinic. The down-regulated
genes in tumor samples are highly enriched for metabolic function
indicating that loss of normal liver function is related to poor
outcome in HCC patients who received surgical treatment. Our
recent study also identified down regulation of microRNA-122
significantly impaired liver mitochondrial metabolic functions in
HCC [41]. In contrast, only the portion of the mouse up-regulated
signature that was also up-regulated in human samples had any,
albeit minimal, predictive power. As the full mouse up-regulated
signature and the subset that is also up-regulated in humans are
enriched for cell cycle processes, we propose that the predictive
power of this set may stem from fundamental properties of the
human tumors, which vary in aggressiveness and presumably the
level of expression of cell cycle genes, compared with the c-MET-
driven mouse tumors, which should be homogeneous.
We observed the greatest difference between human HCC and
the mouse c-MET model with respect to the activity of the p53
pathway. In human HCC, the p53 pathway is frequently
inactivated due to inherited or sporadic mutations in TP53.
Activation of the p53 pathway in the mouse tumors may be part of
a stress response caused by overexpression of the c-MET
oncogene. Inactivation of the p53 pathway in the c-MET mouse
model or overexpression of c-MET in a TP53 mutant mouse may
generate a mouse model that is more highly representative of
human HCC.
Our results highlight the potential value of investing in
molecular profiling of animal models of human disease. The
approach described here is widely applicable to a variety of
diseases for which both relevant animal models and clinical
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samples are readily available. Furthermore, from biomarker
development point of view, any predictive or prognostic
biomarkers need to go through two stages: biomarker identifica-
tion (or hypothesis generation), and biomarker validation (hypoth-
esis testing). This usually requires at least two independent
datasets: training and validation set. Without appropriate
validation set, due to the high dimensional nature (more than
thousands of genes or signatures) of the microarray platform,
signatures derived from the training set are subjective to over
fitting or false positives (a property of multi-testing). Ideally this is
Figure 5. Anti-correlation of metabolic gene signatures with Wnt pathway gene LEF1. Heat map of 250 metabolic genes and their
correlation with LEF1 expression level in (A) mouse c-MET liver tumors and (B) human HCC. Log rank test p-value tested in mouse and human HCC
samples for metabolic genes derived by LEF1 compared with permutation. Spearman’s test was used to calculate the correlation. Mouse tissue types:
0 =WT, 1 =DN, 2 =AN, 3 = TU; human tissue types: 0 =AN; 1 = TU.
doi:10.1371/journal.pone.0024582.g005
Prognostic Gene Signatures of Liver Malignancy
PLoS ONE | www.plosone.org 9 September 2011 | Volume 6 | Issue 9 | e24582
done by two independent clinical cohorts. However, in many cases
they are not readily available. This is especially true for new
treatments entering the early clinical phases (Phase I & II). The
HCC example described above shows it’s possible to use the
mouse model as the first step for signatures (and hypotheses)
generation, to effectively limit the number of hypotheses to a few
(average of up or average of own regulated genes in tumor vs.
normal, in this case), to be quickly tested in the first clinical set
available. By using the mouse model as training set and limiting
the number of hypotheses, we can help to reduce false positives in
clinical setting and speed up the biomarker development.
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Figure S1 Mouse tumor signatures predict human
patient survival. Heat maps show the expression of genes that
were differentially expressed between tumor and distant normal
tissue in the mouse.
(TIF)
Figure S2 Gene expression signatures in both mouse c-
MET liver tumor and human HCC. (A) TP53 pathway
signature shown in the same gene order both in mouse (upper
panel) and human (lower panel) HCC. Tissue types in mouse:
0 =WT, 1=DN, 2=AN, 3=TU; in human: 0 =AN; 1=TU. (B)
Wnt signaling pathway signatures shown in the same gene
order both in mouse (upper panel) and human (lower panel) HCC.
Tissue types in mouse: 0 =WT, 1=DN, 2=AN, 3=TU; in
human: 0=AN; 1=TU.
(TIF)
Figure S3 Genes derived from several mouse models of
HCC have predictive power in human HCC. Log rank test
p-value tested in human HCC samples for genes derived by Lee JS
compared with permutation.
(TIF)
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